Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
17 Juillet 2023 - 1:00PM
Business Wire
Advancing Next-Generation Wearable Patient
Engagement and Diagnostic Technology Designed to Enable More
Efficient Detection of Eye Diseases
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology and pharmaceutical company focused on novel therapies
for the treatment of glaucoma, corneal disorders and retinal
diseases, announced today that it has entered into a collaboration
and marketing agreement with Radius XR, Inc., whereby Glaukos will
become the exclusive sales agent to market, promote and solicit
orders for the Radius XR™ wearable patient engagement and
diagnostic system within the United States. Radius will continue to
lead development and commercialization efforts for Radius XR.
The Radius XR platform is a novel portable vision diagnostic and
patient engagement system designed to enable more efficient
detection of eye disease and better management and treatment of
sight-threatening conditions. It combines medical-grade
diagnostics, business management tools and patient education
resources within a wearable spatial computing device. This
comprehensive hardware and software system provides the tools for
medical professionals to diagnose patients accurately, enhance
patient engagement and reduce staff workload. It enables patients
to perform self-guided vision tests with minimal supervision,
aiding in eye care practices' flow, efficiency and patient
experience.
“Today marks a notable milestone for Radius and more
importantly, for patients suffering from chronic eye diseases.
Glaukos is highly trusted and respected by vision care providers,
and this collaboration will provide us with the necessary resources
to expedite product development, optimize benefits for eye care
providers and enhance the overall quality of care and access for
patients," said Ammad Khan, Radius chief executive officer.
“Through this partnership, Radius will benefit from Glaukos'
market-building expertise, leveraging its well-established sales
team with extensive clinical knowledge and technical insight to
commercialize and drive greater patient access for the Radius XR
technology.”
"We are delighted to partner with Radius to strengthen
commercialization efforts and expand patient access for Radius’
innovative portable vision diagnostic system," said Thomas Burns,
Glaukos chairman and chief executive officer. "We believe the
Radius XR platform is a novel technology that can help drive more
efficient and improved diagnosis for patients suffering from
chronic eye diseases, while also creating efficiency and growth
opportunities for eye care practices. This collaboration aligns
with our mission to meaningfully advance the standard of care and
improve outcomes for patients suffering from chronic eye
diseases."
About Radius XR
The Radius XR platform is a revolutionary portable vision
diagnostic and patient engagement system. It combines medical-grade
diagnostics, business management tools, and patient education
resources within a wearable spatial computing device. The
RadiusExam® and proprietary algorithms provide diagnostic testing
results equivalent to current gold standards demonstrated through a
clinical trial that shows statistical noninferiority of estimated
sensitivities compared to SITA-Standard. This comprehensive
hardware and software system empowers medical professionals to
diagnose patients accurately, enhance patient engagement, and
reduce staff workload. It enables patients to perform self-guided
vision exams with minimal supervision, thereby aiding in the
growth, flow and efficiency of eye care practices.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
and pharmaceutical company focused on developing and
commercializing novel therapies for the treatment of glaucoma,
corneal disorders and retinal diseases. Glaukos first developed
Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS
device commercially in 2012, and continues to develop a portfolio
of technologically distinct and leverageable platforms to support
ongoing pharmaceutical and medical device innovations. Products or
product candidates for each of these platforms are designed to
advance the standard of care through better treatment options
across the areas of glaucoma, corneal disorders and retinal
diseases.
Forward-Looking Statements
All statements other than statements of historical facts
included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may
occur in the future are forward-looking statements. Although we
believe that we have a reasonable basis for forward-looking
statements contained herein, we caution you that they are based on
current expectations about future events affecting us and are
subject to risks, uncertainties and factors relating to our
operations and business environment, all of which are difficult to
predict and many of which are beyond our control, that may cause
our actual results to differ materially from those expressed or
implied by forward-looking statements in this press release. These
potential risks and uncertainties include, without limitation, the
timing and extent to which this investigational product obtains
regulatory approval or clearance, our ability to successfully
market such products, the ability to obtain and maintain adequate
financial coverage and reimbursement for use of this product, and
the continued efficacy and safety profile of this product as
reported in clinical studies. These and other risks, uncertainties
and factors related to Glaukos, and our business are described in
detail under the caption “Risk Factors” and elsewhere in our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2023,
which was filed with the Securities and Exchange Commission (SEC)
on May 4, 2023. Our filings with the SEC are available in the
Investor Section of our website at www.glaukos.com or at
www.sec.gov. In addition, information about the risks and benefits
of our products is available on our website at www.glaukos.com. All
forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary
statements. You are cautioned not to place undue reliance on the
forward-looking statements in this press release, which speak only
as of the date hereof. We do not undertake any obligation to
update, amend or clarify these forward-looking statements whether
as a result of new information, future events or otherwise, except
as may be required under applicable securities law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230717734834/en/
Media Contact: Stefanie Tuck stefanie@jpa.com
Investor Contact: Chris Lewis Vice President, Investor Relations
& Corporate Affairs (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Glaukos (NYSE:GKOS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024